Nuclear medicine techniques for the diagnosis of cardiac amyloidosis: the state of the art

Abstract

Amyloidosis is a disease characterized by the deposition of amorphous protein material in the extracellular space which leads to progressive dysfunction of the affected organ. The forms of amyloidosis that most frequently involve the heart are transthyretin amyloidosis (ATTR) and immunoglobulin light chain amyloidosis (AL). Nuclear medicine offers numerous imaging techniques for the evaluation of patients with cardiac amyloidosis, and in the last decade osteophilic tracer scintigraphy has assumed a fundamental role in the diagnostic process of this disease. New PET radiopharmaceuticals for the detection of amyloid deposits are proving very effective in diagnosing the presence of AL amyloidosis and could soon allow a differential diagnosis without the need for invasive and potentially risky techniques such as endomyocardial biopsy.

Keywords

Amyloidosis / SPECT / PET / ATTR / AL

References

[1] Low YH,Goh AS,Sin FL.Technetium-99m (Tc-99m) diphosphono-propanedicarboxylic acid bone tracer uptake and Tc99m sestamibi distribution in cardiac amyloidosis - a case report.Ann Acad Med Singapore1995;24:898-901

[2] Yen TC,Chen KS.The value of gallium-67 and thallium-201 whole-body and single-photon emission tomography images in dialysis-related beta 2-microglobulin amyloid.Eur J Nucl Med2000;27:56-61

[3] Wechalekar K,Poole-Wilson PA.Cardiac amyloidosis diagnosed incidentally by bone scintigraphy.J Nucl Cardiol2007;14:750-3

[4] Kodama K,Kuwahara T.Rest-redistribution thallium-201 myocardial scintigraphic study in cardiac amyloidosis.Int J Card Imaging1999;15:371-8

[5] Hauser W,Richards P.Amyloidosis of the heart. Possible pitfall in the diagnosis of pericardial effusion by scintillation scanning.JAMA1968;204:628-30

[6] Gerson MC,Fowler NO.Differentiation of constrictive percarditis and restrictive cardiomyopathy by radionuclide ventriculography.Am Heart J1989;118:114-20

[7] Hongo M,Hirayama J,Tanaka M.Radionuclide angiographic assessment of left ventricular diastolic filling in amyloid heart disease: a study of patients with familial amyloid polyneuropathy.J Am Coll Cardiol1989;13:48-53

[8] Clements IP,Scanlon PD,Mullany CJ.The effect of respiration on left ventricular diastolic filling as assessed by radionuclide ventriculography.Nucl Med Commun2000;21:55-63

[9] Arbab AS,Toyama K,Yoshitomi T.Scan findings of various myocardial SPECT agents in a case of amyloid polyneuropathy with suspected myocardial involvement.Ann Nucl Med1997;11:139-41

[10] Ohta H,Kanoh T,Kotoura H.Technetium-99m (V) DMSA uptake in amyloidosis.J Nucl Med1989;30:2049-52

[11] Gazzilli M,Albano D.Cardiac amyloidosis incidentally detected by 18F-FDG PET/CT.J Nucl Cardiol2020;27:2429-31

[12] Tanaka H,Kanagaki M.A case of cardiac amyloidosis incidentally detected by bone scintigraphy.Asia Ocean J Nucl Med Biol2021;9:71-5 PMCID:PMC7701224

[13] Tuominen H,Tikkakoski A,Nikus K.18-FDG-PET in a patient cohort suspected for cardiac sarcoidosis: Right ventricular uptake is associated with pathological uptake in mediastinal lymph nodes.J Nucl Cardiol2020;27:109-17

[14] Tanaka M,Kinoshita O.Iodine-123 metaiodobenzylguanidine scintigraphic assessment of myocardial sympathetic innervation in patients with familial amyloid polyneuropathy.J Am Coll Cardiol1997;29:168-74

[15] Hongo M,Kai R.Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation in patients with AL (primary) amyloidosis.Am Heart J2002;144:122-9

[16] Lekakis J,Prassopoulos V.Myocardial adrenergic denervation in patients with primary (AL) amyloidosis.Amyloid2003;10:117-20

[17] Noordzij W,van Rheenen RW.(123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis.Eur J Nucl Med Mol Imaging2012;39:1609-17 PMCID:PMC3458209

[18] Coutinho MC,Cantinho G.Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.Circ Cardiovasc Imaging2013;6:627-36

[19] Hawkins PN,Pepys MB.Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component.N Engl J Med1990;323:508-13

[20] Hazenberg BP,Piers DA.Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis.Am J Med2006;119:355.e15-24

[21] Aprile C,Saponaro R,Merlini G.Cardiac and pleuropulmonary AL amyloid imaging with technetium-99m labelled aprotinin.Eur J Nucl Med1995;22:1393-401

[22] Schaadt BK,Gimsing P,Pedersen H.99mTc-aprotinin scintigraphy in amyloidosis.J Nucl Med2003;44:177-83

[23] Klunk WE,Nordberg A.Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.Ann Neurol2004;55:306-19

[24] Antoni G,Estrada S.In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET.J Nucl Med2013;54:213-20

[25] Choi SR,Zhuang Z.Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.J Nucl Med2009;50:1887-94 PMCID:PMC3065020

[26] Wong DF,Zhou Y.In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).J Nucl Med2010;51:913-20 PMCID:PMC3101877

[27] Yang L,Ganley C.Brain amyloid imaging--FDA approval of florbetapir F18 injection.N Engl J Med2012;367:885-7

[28] Dorbala S,Semer J.Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography.Eur J Nucl Med Mol Imaging2014;41:1652-62

[29] Vandenberghe R,Ivanoiu A.18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.Ann Neurol2010;68:319-29

[30] Lhommel R,Ivanoiu A,Gerber B.Is 18F-flutemetamol PET/CT able to reveal cardiac amyloidosis?.Clin Nucl Med2014;39:747-9

[31] Dietemann S.Amyloid PET imaging in cardiac amyloidosis: a pilot study using ¹⁸F-flutemetamol positron emission tomography.Ann Nucl Med2019;33:624-8

[32] Möckelind S,Pilebro B,Suhr OB.Quantification of cardiac amyloid with [¹⁸F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis.Amyloid2020;27:191-9

[33] Rowe CC,Browne W.Imaging of amyloid β in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism.Lancet Neurol2008;7:129-35

[34] Law WP,Moore PT,Ng AC.Cardiac amyloid imaging with 18F-Florbetaben PET: a pilot study.J Nucl Med2016;57:1733-9

[35] Kircher M,Brumberg J.Detection of cardiac amyloidosis with ¹⁸F-Florbetaben-PET/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy.Eur J Nucl Med Mol Imaging2019;46:1407-16

[36] Genovesi D,Giorgetti A.[18F]-Florbetaben PET/CT for Differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions.JACC Cardiovasc Imaging2021;14:246-55

[37] Kula R,Line B.Scanning for soft-tissue amyloid.Lancet1977;309:92-3

[38] Perugini E,Salvi F.Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy.J Am Coll Cardiol2005;46:1076-84

[39] Rapezzi C,Guidalotti PL.Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy.Eur J Nucl Med Mol Imaging2011;38:470-8

[40] Kristen AV,Schonland SO.Skeletal scintigraphy indicates disease severity of cardiac involvement in patients with senile systemic amyloidosis.Int J Cardiol2013;164:179-84

[41] Rapezzi C,Guidalotti PL.Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.JACC Cardiovasc Imaging2011;4:659-70

[42] Falk RH,Rubinow A,Cohen AS.Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis.Am J Cardiol1983;51:826-30

[43] Bokhari S,Pozniakoff T,Latif F.(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.Circ Cardiovasc Imaging2013;6:195-201 PMCID:PMC3727049

[44] Cappelli F,Di Mario C.Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis.J Nucl Cardiol2019;26:497-504

[45] Gillmore JD,Falk RH.Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.Circulation2016;133:2404-12

[46] Dorbala S,Bokhari S.ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.J Nucl Cardiol2019;26:2065-123

[47] Musumeci MB,Russo D.Low sensitivity of bone scintigraphy in detecting Phe64Leu mutation-related transthyretin cardiac amyloidosis.JACC Cardiovasc Imaging2020;13:1314-21

[48] Pilebro B,Näslund U,Lindqvist P.(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.Ups J Med Sci2016;121:17-24 PMCID:PMC4812053

[49] Wakfie-Corieh CG,Saiz-Pardo Sanz M,Vilacosta I.Not all heart uptakes on 99mTc-DPD scintigraphy are amyloidosis: chloroquine-induced cardiomyopathy.Clin Nucl Med2021;46:e188-9

[50] Chimenti C,Maestrini V.False-positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy.ESC Heart Fail2021;

[51] Stats MA.Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis.Cardiovasc Pathol2016;25:413-7

[52] Segall G,Stabin MG.SNMSNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0.J Nucl Med2010;51:1813-20

[53] Trivieri MG,Abgral R.¹⁸F-Sodium fluoride PET/MR for the assessment of cardiac amyloidosis.J Am Coll Cardiol2016;68:2712-4 PMCID:PMC5438164

[54] Morgenstern R,Castano A,Bokhari S.¹⁸Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis.J Nucl Cardiol2018;25:1559-67

[55] Ng QKT,Saunders TA,Flavell RR.Discordant findings on 18F-NaF and 99mTc-HDP bone scans in a patient with ATTR cardiac amyloidosis.Clin Nucl Med2018;43:e89-92

[56] Zhang LX,Finnerty V.Comparison of 18F-sodium fluoride positron emission tomography imaging and 99mTc-pyrophosphate in cardiac amyloidosis.J Nucl Cardiol2020;